LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
LumiraDx Limited (Nasdaq: LMDX) announced the release of its third quarter financial results on November 9, 2022. The company will conduct a conference call at 8:00 AM Eastern Time to discuss these results and business highlights. LumiraDx focuses on next-generation point of care diagnostics, providing lab-comparable tests for various medical conditions via its microfluidic technology. Founded in 2014, the company offers over 30 assays and serves global healthcare institutions, emphasizing community-based healthcare solutions.
- Next-generation diagnostics technology provides accessible testing solutions.
- Broad menu of over 30 assays for various medical conditions.
- None.
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
| LumiraDx Third Quarter 2022 Financial Results Conference Call | |
| Date: | Wednesday, November 9, 2022 |
| Time: | 8:00 AM Eastern Time |
| Live Call/Webcast: | Register to join by phone here. |
| View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar |
A replay of the webcast will be available on the Investors section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.
About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need. The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. More information on LumiraDx is available at www.lumiradx.com.
Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com
FAQ
When will LumiraDx release its third quarter financial results?
What time is the LumiraDx conference call scheduled for?
What is the focus of LumiraDx's diagnostic technology?
How many assays does LumiraDx currently offer?
